

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Mail Stop PCT/Sequence, Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313 on:

September 21, 2006

David Saliwanchik
David R. Saliwanchik, Patent Attorney

AMENDMENT UNDER
37 CFR 1.825(a) THROUGH (c)
Confirmation No. 2899
Patent Application
Docket No. SPO-125
Serial No. 10/568,033

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Toshihiro Nakajima *et al.*
Serial No. : 10/568,033
Filed : February 10, 2006
Conf. No. : 2899
For : Therapeutic Preparation for Hematopoietic Disease

Mail Stop PCT/Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUBMISSION OF:
SEQUENCE LISTING UNDER 37 CFR §1.821 &
AMENDMENT UNDER 37 CFR 1.825(a) THROUGH (c)

Sir:

In response to the Notification of Missing Requirements regarding the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures received in the above-identified patent application, please amend the subject application as follows: